CASE REPORT
Rhabdomyosarcoma of the left atrium of the heart in a child – case report
Submission date: 2018-08-04
Final revision date: 2018-09-21
Acceptance date: 2018-10-14
Publication date: 2018-10-30
Pediatr Pol 2018;93(5):424-428
KEYWORDS
TOPICS
ABSTRACT
Primary tumours of the heart are rare in children. Most of them are benign. Sarcomas predominate among malignant tumours and are characterised by disadvantageous prognosis, especially in the presence of metastases. We present a case of a 16-year-old boy admitted to the hospital with signs of worsening exercise tolerance and suspected left atrial myxoma. The patient was urgently treated with cardiac surgery. Only partial tumour resection was possible. Rhabdomyosarcoma (RMS) embryonale was diagnosed. Stage IV of the disease was established (metastases to the left lung). A good initial response to chemotherapy was observed. In control studies, during the maintenance chemotherapy (15 months from the diagnosis of RMS) progression of the disease (PD) was found: right forearm tumour with metastasis near the left adrenal gland. Despite the intensification of treatment, there was resistance to successive lines of chemotherapy. The patient died of the disease progression.
REFERENCES (24)
1.
Gunther T, Schreiber C, Noebauer C, et al. Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: a 30-year review. Pediatr Cardiol 2008; 29: 1071-1076.
2.
Schaffer LR, Caltharp SA, Milla SS, et al. Rare presentation of four primary pediatric cardiac tumors. Cardiovasc Pathol 2016; 25: 72-77.
3.
Monge MC, Walterhouse DO, Kalapurakal JA, et al. Resection of Intrapericardial Rhabdomyosarcoma in a Child. World J Pediatr Congenit Heart Surg 2016; 7: 108-111.
4.
Uzun O, Wilson DG, Vujanic GM, et al. Cardiac tumours in children. Orphanet J Rare Dis 2007; 2: 11.
5.
Egas-Bejar D, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther 2014; 5: 115-125. TABLE 1. Recently published research concerning the use of targeted therapy in rhabdomyosarcoma in children Author of the study Year of publication Name of the drug Targeted pathway Research stage Fouladi M et al. [19] 2010 vorinostat histone deacetylases (HDAC) First phase Mascarenhas L et al. [20] 2014 temsirolimus vs. bevacizumab mTOR kinase vs. VEGF Second phase Kim A et al. [21] 2015 sorafenib C-RAF, B-RAF, VEGFR-2,-3, PDGFR-β, FLT3, c-KIT Second phase Lee A et al. [22] 2015 pazopanib VEGFR-1,-2,-3, PDGFR-α,-β, FGFR, c-KIT Second phase Chisholm JC et al. [23] 2017 bevacizumab VEGF Second phase Glod J et al. [24] 2018 cediranib VEGFR-1,-2,-3 Second phase.
6.
Kazanowska B, Węcławek-Topol J. Mięsaki tkanek miękkich. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – 2013 r. Tom 3, Krzakowski M, Warzocha K. Via Medica, Gdańsk 2014: 1124-1149.
7.
Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 2006; 24: 3844-3851.
8.
Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer 2008; 113: 3242-3247.
9.
Ma J, Sun JP, Chen M, et al. Left Atrial Rhabdomyosarcoma. Circulation 2014; 129: e503-e505.
10.
Kirkpatrick JN, Wong T, Bednarz JE, et al. Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol 2004; 43: 1412-1419.
11.
Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26: 2384-2389.
12.
Dantonello TM, Winkler P, Boelling T, et al. Embryonal rhabdomyosarcoma with metastases confined to the lungs: report from the CWS Study Group. Pediatr Blood Cancer 2011; 56: 725-732.
13.
Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007; 67: 10-18.
14.
Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002; 29: 2391-2403.
15.
Grandmougin D, Fayad G, Decoene C, et al. Total orthotopic heart transplantation for primary cardiac rhabdomyosarcoma: factors influencing long-term survival. Ann Thorac Surg 2001; 71: 1438-1441.
16.
Selman AR, Ubilla SM, Espinoza HJ, et al. Heart autotransplantation for the treatment of a rhabdomyosarcoma of the left ventricle. Report of one case. Rev Med Chil 2012; 140: 775-779.
17.
Yang JC, Wexler LH, Meyers PA, et al. Intensity-modulated radiation therapy with dose-painting for pediatric sarcomas with pulmonary metastases. Pediatr Blood Cancer 2013; 60: 1616-1620.
18.
Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010; 12: 402-410.
19.
Fouladi M, Park JR, Stewart CF, et al. Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol 2010; 28: 3623-3629.
20.
Mascarenhas L, Meyer WH, Lyden E, et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/ disease progression of rhabdomyosarcoma (RMS): a report from the Children’s Oncology Group (COG). J Clin Oncol 2014; 32 (Suppl): 10003-10003.
21.
Kim A, Widemann BC, Krailo M, et al. Phase 2 trial of Sorafenib in Children and Young Adults with Refractory Solid Tumors: A Report from the Children’s Oncology Group. Pediatr Blood Cancer 2015; 62: 1562-1566.
22.
Lee A, Bender JG, Weigel B, et al. A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors. J Clin Oncol 2015; 33 [ahead of print]. DOI: 10.1200/jco.2015.33.15_ suppl.tps10081.
23.
Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer 2017; 83: 177-184.
24.
Glod J, Cohen JW, Widemann BC, et al. Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS). J Clin Oncol 2018; 36 (Suppl): 10540-10540.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
